The weekly litigation news digest is live. Subscribe now
Cladribine Regimen For Treating Multiple Sclerosis - EP4070800
The patent EP4070800 was granted to Merck Serono on Oct 16, 2024. The application was filed on Dec 20, 2005 under application number EP22166610A. The patent is currently recorded with a legal status of "Granted And Under Opposition".
EP4070800
- Application Number
- EP22166610A
- Filing Date
- Dec 20, 2005
- Status
- Granted And Under Opposition
- Sep 13, 2024
- Publication Date
- Oct 16, 2024
- External Links
- Slate, Register, Google Patents
Patent Summary
A method for treating multiple sclerosis using oral cladribine, comprising an induction treatment of 1-7 days of cladribine administration per month for 2-4 months, followed by a 2-10 month cladribine-free period, and then a maintenance treatment of 1-7 days of cladribine administration per month for 2-4 months. The treatment can be repeated for a total duration of 2-4 years.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Patent Citations (15) New
Patent citations refer to prior patents cited during different phases such as opposition or international search.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents